ABBV News and Press, AbbVie Inc. From 06/17/24

2024-06-17 15:37:41 ET Summary For dividend growth investing, is growth more important than valuation? 49 stocks are valued based on Historical and Future Fair Valuations as well as analyst estimates. 49 stocks are further evaluated based on past dividend growth and future pro...

2024-06-17 11:30:03 ET Summary Amgen continues to delight investors with the growth in sales of its key blockbusters and the expansion of its portfolio of medications. In mid-June, Amgen pleased investors by announcing that the FDA had approved Blincyto to treat certain patients w...

2024-06-16 08:30:00 ET People invest in dividend stocks for various reasons. Some want the passive income; others reinvest the cash to boost long-term returns; still others find that corporations that can dish out regular (and growing) payouts are worth investing in. But few such investors ...

2024-06-16 08:12:27 ET Summary In recent months, Incyte's management has continued to delight investors by accelerating the pace of development of its anti-inflammatory treatments. On May 30, 2024, Incyte announced the completion of its acquisition of Escient Pharmaceuticals for $...

2024-06-15 15:37:28 ET The market for medicines to treat amyotrophic lateral sclerosis (ALS) in major markets is projected to more than surge to $1.28B in 2029 from $317M in 2019, representing a CAGR of 15%.... Read the full article on Seeking Alpha For further details see: ...

2024-06-14 17:03:24 ET More on AbbVie AbbVie, Inc. (ABBV) Goldman Sachs 45th Annual Global Healthcare Conference (Transcript) AbbVie: Turnaround Lurking After The Correction Pain (Upgrade) AbbVie: This Dividend Aristocrat Is Almost Buyable Again Now AbbVie in...

AbbVie Recommends Shareholders Reject Tutanota's "Mini-Tender" Offer PR Newswire NORTH CHICAGO, Ill. , June 14, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) has been notified that Tutanota LLC (Tutanota) has commenced an unsolicited "mini-tender" offer, dated May 2...

2024-06-14 13:26:47 ET Summary Disc Medicine, Inc. released positive results from the phase 2 AURORA study, using bitopertin for the treatment of patients with EPP and XLP. Potential FDA feedback to initiate a pivotal study using bitopertin for the treatment of patients with EPP a...

2024-06-13 14:03:52 ET Summary Contineum Therapeutics, Inc. PIPE-791 is being developed for the treatment of neuroinflammatory disorders like idiopathic pulmonary fibrosis and Progressive Multiple Sclerosis. The global idiopathic pulmonary fibrosis market size is projected to reac...

2024-06-13 13:54:33 ET More on Cerevel Therapeutics Cerevel Therapeutics: Time For A Risk Arbitrage Play? Cerevel Therapeutics gains after AbbVie says making good progress with FTC AbbVie buyout Cerevel posts late-stage win for Parkinson’s disease drug ...